Spyre Therapeutics

Spyre (SYRE) Jumps 42% as Treatment Candidate Shows ‘Best-in-Class’ Potential

amefika2 months ago02 mins

Spyre Therapeutics Inc. (NASDAQ:SYRE) is one of the Ten stocks with monstrous returns. Spyre Therapeutics surged its stock price 42.3 percent week over week as investors took heart from the “best-in-class” potential of its ulcerative colitis (UC) therapy candidate. In a report updated earlier in the week, Spyre Therapeutics Inc. (NASDAQ:SYRE) said its treatment candidate,…

Spyre Therapeutics Shares Rise Last Year as .5 Million Purchase Raises Stake to Million

Spyre Therapeutics Shares Rise Last Year as $10.5 Million Purchase Raises Stake to $78 Million

amefika3 months ago04 mins

Commodore Capital announced the purchase of 400,161 shares of Spyre Therapeutics (NASDAQ:SYRE)an estimated trade of $10.46 million based on quarterly average price, according to an SEC filing dated February 17, 2026. According to an SEC filing dated February 17, 2026, Commodore Capital increased its position in Spyre Therapeutics by 400,161 shares during the fourth quarter….